JP2000500662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000500662A5 JP2000500662A5 JP1998508568A JP50856898A JP2000500662A5 JP 2000500662 A5 JP2000500662 A5 JP 2000500662A5 JP 1998508568 A JP1998508568 A JP 1998508568A JP 50856898 A JP50856898 A JP 50856898A JP 2000500662 A5 JP2000500662 A5 JP 2000500662A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR96/09584 | 1996-07-30 | ||
| FR9609584A FR2751879B1 (fr) | 1996-07-30 | 1996-07-30 | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| PCT/FR1997/001412 WO1998004705A1 (fr) | 1996-07-30 | 1997-07-29 | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007092639A Division JP4198735B2 (ja) | 1996-07-30 | 2007-03-30 | パピローマウイルス腫瘍および感染を治療するための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000500662A JP2000500662A (ja) | 2000-01-25 |
| JP2000500662A5 true JP2000500662A5 (enExample) | 2004-11-18 |
| JP4070815B2 JP4070815B2 (ja) | 2008-04-02 |
Family
ID=9494633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50856898A Expired - Fee Related JP4070815B2 (ja) | 1996-07-30 | 1997-07-29 | パピローマウイルス腫瘍および感染を治療するための医薬組成物 |
| JP2007092639A Expired - Fee Related JP4198735B2 (ja) | 1996-07-30 | 2007-03-30 | パピローマウイルス腫瘍および感染を治療するための医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007092639A Expired - Fee Related JP4198735B2 (ja) | 1996-07-30 | 2007-03-30 | パピローマウイルス腫瘍および感染を治療するための医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP0862634B2 (enExample) |
| JP (2) | JP4070815B2 (enExample) |
| AT (2) | ATE265535T1 (enExample) |
| AU (1) | AU736720B2 (enExample) |
| CA (1) | CA2234263C (enExample) |
| DE (2) | DE69728914T2 (enExample) |
| DK (2) | DK1149910T3 (enExample) |
| ES (2) | ES2215805T3 (enExample) |
| FR (1) | FR2751879B1 (enExample) |
| HK (1) | HK1043809B (enExample) |
| PT (2) | PT1149910E (enExample) |
| WO (1) | WO1998004705A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
| US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
| US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
| WO2000000217A1 (fr) * | 1998-06-26 | 2000-01-06 | Aventis Pasteur | Immunisation a ciblage mucosal |
| ES2671230T3 (es) | 2006-06-20 | 2018-06-05 | Transgene Sa | Procedimiento para producir poxvirus y composiciones de poxvirus |
| HUE025015T2 (en) | 2009-01-20 | 2016-04-28 | Transgene Sa | Soluble in ICAM-1 as a biomarker for predicting therapeutic response |
| DK2411815T3 (en) | 2009-03-24 | 2015-11-30 | Transgene Sa | Biomarker MONITORING OF PATIENTS |
| US20120058493A1 (en) | 2009-04-17 | 2012-03-08 | Bruce Acres | Biomarker for monitoring patients |
| SG176554A1 (en) | 2009-05-12 | 2012-01-30 | Transgene Sa | Method for orthopoxvirus production and purification |
| CN102483405B (zh) | 2009-07-10 | 2015-12-02 | 特朗斯吉有限公司 | 用于选择患者的生物标志物及相关方法 |
| MX2012000979A (es) | 2009-07-21 | 2012-06-08 | Transgene Sa | Composición enzimática para la digestión de embriones de pollo. |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| MX378901B (es) | 2014-12-01 | 2025-03-10 | Transgene Sa | Formulaciones liquidas estables de virus de vacuna. |
| FR3042121A1 (fr) * | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| US11052147B2 (en) | 2017-05-15 | 2021-07-06 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2020049151A1 (en) | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| US20230114464A1 (en) | 2020-03-12 | 2023-04-13 | Bavarian Nordic A/S | Conditions Improving Poxvirus Stability |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2643817B1 (fr) * | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| IE910909A1 (en) † | 1990-03-20 | 1991-09-25 | Behringwerke Ag | Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins |
| GB9113809D0 (en) * | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
| DK1298211T3 (da) * | 1991-07-19 | 2006-11-13 | Univ Queensland | Polynukleotidsegment af HPV16-genom |
| US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
| GB9306731D0 (en) * | 1993-03-31 | 1993-05-26 | Cancer Res Campaign Tech | Vaccines |
| IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide vaccne for papillomavirus |
| EP0789774A2 (en) * | 1994-10-03 | 1997-08-20 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
| GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
| FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
-
1996
- 1996-07-30 FR FR9609584A patent/FR2751879B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-29 DK DK01109013T patent/DK1149910T3/da active
- 1997-07-29 DE DE69728914T patent/DE69728914T2/de not_active Expired - Lifetime
- 1997-07-29 EP EP97935646A patent/EP0862634B2/fr not_active Expired - Lifetime
- 1997-07-29 DK DK97935646T patent/DK0862634T4/da active
- 1997-07-29 ES ES01109013T patent/ES2215805T3/es not_active Expired - Lifetime
- 1997-07-29 PT PT01109013T patent/PT1149910E/pt unknown
- 1997-07-29 EP EP01109013A patent/EP1149910B1/fr not_active Expired - Lifetime
- 1997-07-29 WO PCT/FR1997/001412 patent/WO1998004705A1/fr not_active Ceased
- 1997-07-29 AT AT01109013T patent/ATE265535T1/de active
- 1997-07-29 CA CA002234263A patent/CA2234263C/fr not_active Expired - Fee Related
- 1997-07-29 DE DE69706825T patent/DE69706825T3/de not_active Expired - Lifetime
- 1997-07-29 AT AT97935646T patent/ATE205881T1/de active
- 1997-07-29 PT PT97935646T patent/PT862634E/pt unknown
- 1997-07-29 ES ES97935646T patent/ES2163795T5/es not_active Expired - Lifetime
- 1997-07-29 JP JP50856898A patent/JP4070815B2/ja not_active Expired - Fee Related
- 1997-07-29 AU AU38552/97A patent/AU736720B2/en not_active Ceased
-
2002
- 2002-04-30 HK HK02103266.9A patent/HK1043809B/zh not_active IP Right Cessation
-
2007
- 2007-03-30 JP JP2007092639A patent/JP4198735B2/ja not_active Expired - Fee Related